Exporting Cannabis Products from the UK: Regulations and Obligations

UK Export Licensing for Controlled Drugs

• Cannabis products classified as Schedule 2 controlled drugs require an export licence from the Home Office
• Export licences specify the product, quantity, destination country, and recipient
• The importing country must issue a corresponding import authorisation before export
• Licences are typically valid for a limited period and for a single consignment

Exporting cannabis products from the United Kingdom is governed by the same Home Office licensing regime that applies to imports. Companies wishing to export — whether finished medicinal products, active pharmaceutical ingredients, or cultivated plant material — must obtain specific export licences and ensure the receiving country has provided the necessary import authorisations before goods can move.

MHRA Export Certificates and Batch Release

• Exported medicinal products may require a Certificate for Pharmaceutical Products from the MHRA
• Batch release certification demonstrates compliance with manufacturing standards
• Some destination markets require UK-issued batch release certificates as a condition of import
• The MHRA provides guidance on export documentation requirements for different markets

Beyond controlled drug licensing, the medicinal product aspects of cannabis exports may require MHRA involvement. Destination countries frequently require export certificates confirming that products are manufactured in compliance with GMP standards recognised in the UK. Building export documentation processes into manufacturing workflows from the outset avoids delays at the point of export.

Key Export Destination Considerations

• Germany, the Netherlands, and Australia are among the most significant markets for UK-exported cannabis medicines
• Each destination country has its own import authorisation process and product approval requirements
• Some markets require specific product registrations that can take considerable time to obtain
• Currency, logistics, and cold chain considerations vary significantly by destination

The attractiveness of the UK as a manufacturing and export base for medical cannabis is significant, particularly given its existing pharmaceutical infrastructure and international trade relationships. However, navigating the import requirements of individual destination markets requires country-specific regulatory expertise. A one-size-fits-all approach to export compliance will not succeed across diverse international markets.

Post-Export Obligations and Pharmacovigilance

• Exported medicinal products remain subject to pharmacovigilance obligations
• Serious adverse events reported in export markets may require notification to the MHRA
• Product recalls initiated in export markets must be managed in coordination with UK authorities
• Export records must be maintained and available for inspection by UK regulators

The obligations of a medical cannabis exporter do not end when the consignment clears UK customs. Post-market surveillance, adverse event reporting, and recall management requirements continue to apply to exported products. Companies entering export markets should establish pharmacovigilance systems that capture data from all markets in which their products are sold, and ensure these feed back into their UK regulatory compliance processes.